טוען...
PHARMACOECONOMIC ISSUES OF ADALIMUMAB THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS
Background. Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children and is associated with reduced quality of life and increased health care costs. Objective. To evaluate the cost effectiveness of the tumour necrosis factor inhibitor adalimumab (ADA) vs. non-biologic the...
שמור ב:
| Main Authors: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Paediatrician Publishers, LLC
2012-08-01
|
| סדרה: | Pediatričeskaâ Farmakologiâ |
| נושאים: | |
| גישה מקוונת: | https://www.pedpharma.ru/jour/article/view/302 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|